RxDoctor Payments DataLook up a doctor →

Neil Soni, MD

Hospice and Palliative Medicine · Fountain Valley, CANPI 1306054150

Payments from drug & device makers

$27,624in general payments, 2019–2025

Across 642 payments — averaging $43.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$14K
  • Abbott$2K
  • Boston Scientific$887
  • Saluda Medical Americas, Inc.$881
  • Amgen$821
  • USWM, LLC$808
  • plus $8K from 54 others

What the payments were for

  • Speaking & faculty fees$12,91347%
  • Food & beverage$14,16351%
  • Education$420%
  • Gifts$5062%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)81$13,805
Abbott43$2,138
Boston Scientific27$887
Saluda Medical Americas, Inc.30$881
Amgen36$821
USWM, LLC19$808
GSK31$668
Collegium Pharmaceutical, Inc.37$642
Protega Pharmaceutials Inc4$549
Johnson & Johnson(3 entities)27$503
Medtronic(2 entities)12$485
Pfizer25$433
Regeneron Healthcare Solutions, Inc.15$397
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC25$364
Scilex Pharmaceuticals Inc.13$246
Grifols USA, LLC9$244
Nevro Corp.7$213
Novartis10$185
Daiichi Sankyo Inc.25$185
Actelion Pharmaceuticals US, Inc.5$177
Lilly USA, LLC9$171
Novo Nordisk3$155
AstraZeneca7$141
Tersera Therapeutics LLC10$141
Eisai Inc.9$136
Vertex4$128
MDD US Operations, LLC9$127
Averitas Pharma Inc.5$120
Baxter Healthcare3$104
Biohaven Pharmaceutical Holding Company Ltd.4$103
Biohaven Pharmaceuticals, Inc.5$92
Teva Pharmaceuticals USA, Inc.4$88
Sentynl Therapeutics, Inc.6$87
Biotronik NRO, Inc.4$84
Gilead6$84
Advanced Respiratory, Inc4$84
Otsuka America Pharmaceutical, Inc.4$83
Biodelivery Sciences International, Inc.6$80
Hikma Pharmaceuticals USA4$78
Electromed, Inc.3$60
Axsome Therapeutics, Inc.2$55
Pulmonx Corporation2$53
Idorsia Pharmaceuticals US Inc3$50
Valinor Pharma, LLC2$45
Boehringer Ingelheim2$41
E.r. Squibb & Sons, L.L.C.2$38
Redhill Biopharma Inc.2$37
Upsher-smith Laboratories LLC2$37
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)2$35
Almatica Pharma LLC3$35
ERMI LLC2$33
Arbor Pharmaceuticals, Inc.2$32
Forte Bio-pharma LLC2$29
Globus Medical1$25
Orexo US, Inc.1$24
ANI Pharmaceuticals, Inc.1$23
Sun Pharmaceutical Industries Inc.1$22
Insmed, Inc.1$21
Takeda Pharmaceuticals U.S.A., Inc.1$20
Masimo Corporation1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,624 in reported general payments places this provider in the 95th percentile of 195 hospice and palliative medicine providers in California.

See all hospice and palliative medicine providers in California

Medicare billing

Part B allowed, 2024
$1,084,095
Medicare patients
641
Services billed
16,627

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RelistorMethylnaltrexone Bromide39$109,121
OxycontinOxycodone Hcl90$89,087
UbrelvyUbrogepant59$84,689
LucemyraLofexidine Hcl19$83,068
NucyntaTapentadol Hcl25$56,705
Xtampza ErOxycodone Myristate53$46,697
QuliptaAtogepant31$42,554
MovantikNaloxegol Oxalate70$33,268
Lidocaine163$26,372
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen668$24,838
BelbucaBuprenorphine Hcl26$24,491
Aimovig AutoinjectorErenumab-Aooe23$16,800
ZenpepLipase/Protease/Amylase38$15,815
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen391$15,733
BotoxOnabotulinumtoxina12$15,396

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor, Lucemyra$364$192,18958 claims
AbbVieUbrelvy, Qulipta, Botox$13,805$142,639102 claims
Collegium Pharmaceutical, Inc.Nucynta, Xtampza Er, Belbuca$642$127,892104 claims
Redhill Biopharma Inc.Movantik$37$33,26870 claims
Hikma Pharmaceuticals USABuprenorphine-Naloxone, Morphine Sulfate$78$16,183201 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 195 hospice and palliative medicine providers in California.

Other hospice and palliative medicine in Fountain Valley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →